European Notebook: Rasi To Review EMA Plans; Spain’s Drug Spend Held Flat By Industry; Insurers Merge In Germany
Re-appointed EMA Executive Director Guido Rasi will outline his plans for the agency in early December; pact in Spain calls for the pharmaceutical industry to reimburse government for spending increases above GDP growth.
You may also be interested in...
By buying U.S.-based Sigma-Aldrich, the German conglomerate hopes to bolster its Millipore lab business, by giving the biopharma technology, tools and service provider added depth and global reach.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.